Drug Profile
Research programme: anti-infectives - Cubist/Merck
Alternative Names: Anti-infectives research programme - MerckLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Cubist Pharmaceuticals; Merck & Co
- Class
- Mechanism of Action Amino acyl tRNA synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 31 Aug 2006 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 30 May 2001 Preclinical development for Bacterial infections in USA (Unknown route)